Trial · NCT01147601
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
NCT01147601, Early phase 1, Terminated, Oregon Health and Science University; results first posted 2017-07-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas. Trials, record NCT01147601. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01147601
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
- NCT number
- NCT01147601
- Status
- Terminated
- Phases
- Early phase 1
- Enrollment
- 6 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Hemangioma, Infant
- Interventions
- topical 0.5% Timolol, Control (placebo) group
- First posted
- 2010-06-22
- Last updated
- 2017-07-05
- Results first posted
- 2017-07-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos. | at 6 months | This will be generated by asking each of the assessors to score the improvement using a visual analog scale (VAS) assessing the decrease in size of hemangioma by comparing photographs at different times of treatment. The assessors will score this improvement into one of the following categories: 0-24%, 25-49%, 50-74%, \>75%. |
| Secondary | Compare Treatment Group to Control Group Improvement Assessments | at 6 months | 1. The proportion of subjects in the treatment group as compared to the placebo control group with at least 50% improvement in the extent of the hemangioma. 2. The difference between the extent/size of the hemangioma as an outcome measure versus color changes. 3. Frequency of adverse events (e.g. hypotension, behavioral changes, etc.), collected by the investigator and reported by the parents. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos. | at 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Compare Treatment Group to Control Group Improvement Assessments | at 6 months |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos. | Topical 0.5% Timolol | 1 | Participants | ||
| Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos. | Placebo | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topical 0.5% Timolol | 5 | |
| Overall Study | STARTED | Placebo | 1 | |
| Overall Study | COMPLETED | Topical 0.5% Timolol | 2 | |
| Overall Study | COMPLETED | Placebo | 1 | |
| Overall Study | NOT COMPLETED | Topical 0.5% Timolol | 3 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper Respiratory Infection | Respiratory, thoracic and mediastinal disorders | Topical 0.5% Timolol | 1 | 5 | 1 |
| other | Upper Respiratory Infection | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 1 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topical 0.5% Timolol | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Topical 0.5% Timolol | 1 | 5 |
| Total, other adverse events | Placebo | 0 | 1 |
| Total, serious adverse events | Topical 0.5% Timolol | 0 | 5 |
| Total, serious adverse events | Placebo | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Topical 0.5% Timolol vs Placebo: Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos. | Trial comparisons |
| Topical 0.5% Timolol vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01147601
GET https://conductscience.org/api/trials/v1/NCT01147601/registered